ArticleFrontiers in public health2025
Rapid public health genomics capacity building during the COVID-19 Delta crisis driven by a transnational private, public, and social alliance.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When the COVID-19's Delta variant spread globally during late 2020, Public Health Genomics (PHG) capabilities were missing in several cities, significantly impairing the ability of policymakers and public health systems to rapidly identify COVID-19 variants and effectively respond, with tragic human and economic consequences. In this community case study, we retrospectively studied the dire situation during the Delta wave 5 years ago when we rapidly constituted a transnational public, private, and social, pro-bono alliance to establish PHG capabilities in Mumbai, a mega metropolis that lacked this capacity. The Albright Stonebridge Group-a renowned global commercial diplomacy entity, Illumina-a genomic sequencing equipment leader, a leading Mumbai non-governmental organization-the ATE Chandra Foundation, and the Municipal Corporation of Greater Mumbai, came together in an alliance to rapidly establish PHG capabilities in Mumbai. This effort was coordinated across multiple countries, with distributed decision-making and defined responsibilities. An optimal site for a PHG center in Mumbai was identified, and the operational requirements, governance structures, resource and sustainability requirements were defined. In 3 months, the Genome Sequencing Centre for Outbreak Preparedness & Epidemiology (GeSCOPE) was successfully established in Mumbai's public infectious disease hospital, Kasturba. The percentage of samples sequenced increased from less than 1% to over 30%, including all known RT-PCR positive cases, the sequencing time dropped to under 72 h, and public health policy and responses were enhanced. Currently, GeSCOPE has established itself as the epidemiological hub for Mumbai and western India at large, identifying infectious disease threats such as Dengue, Chikungunya, and drug resistance genes in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.